Skip to main content
logo
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
15.40
-0.51 (-3.21%)
Jul 8, 2026, 4:00 PM EDT - Market closed

Lyell Immunopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.030.040.060.1384.6810.65
Revenue Growth (YoY)
-52.31%-40.98%-53.08%-99.85%695.15%37.31%
Gross Profit
0.030.040.060.1384.6810.65
Selling, General & Admin
40.6445.1452.0466.98117.3189.06
Research & Development
151.83225.01258.79182.95159.19138.69
Other Operating Expenses
-2.48-0.747.99-2.79-4.75-2.32
Total Operating Expenses
190269.44358.82247.14271.74225.43
Operating Income
-256.3-269.4-358.76-247.01-187.06-214.78
Interest Income
11.4113.0824.0723.457.051.17
Other Non-Operating Income (Expense)
4.86-18.12-8.31-11.08-3.11-36.61
Total Non-Operating Income (Expense)
9.89-5.0415.7612.383.94-35.44
Pretax Income
-246.41-274.45-342.99-234.63-183.12-250.22
Net Income
-246.41-274.45-342.99-234.63-183.12-250.22
Net Income to Common
-246.41-274.45-342.99-234.63-183.12-250.22
Shares Outstanding (Basic)
19171313127
Shares Outstanding (Diluted)
19171313127
Shares Change (YoY)
38.86%30.74%4.18%1.58%81.79%925.18%
EPS (Basic)
-13.80-16.06-26.23-18.70-14.80-36.80
EPS (Diluted)
-13.80-16.06-26.23-18.70-14.80-36.80
Free Cash Flow
-134.42-150.8-162.86-166.38-193.83-191.75
Free Cash Flow Per Share
-7.13-8.82-12.46-13.26-15.69-28.22
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-826768.00%-748344.00%-588123.00%-190006.00%-220.89%-2016.68%
Profit Margin
-794858.00%-762356.00%-562285.00%-180486.00%-216.24%-2349.47%
FCF Margin
-433610.00%-418900.00%-266980.00%-127985.00%-228.89%-1800.50%
EBITDA
-245.87-257.87-339.12-226.76-169.04-201.15
EBITDA Margin
-793123.00%-716292.00%-555941.00%-174429.00%-199.61%-1888.75%
EBIT
-256.3-269.4-358.76-247.01-187.06-214.78
EBIT Margin
-826768.00%-748344.00%-588123.00%-190006.00%-220.89%-2016.68%
SEC Filings: 10-K · 10-Q